Lineage Cell Therapeutics Future Growth
Future criteria checks 2/6
Lineage Cell Therapeutics is forecast to grow earnings and revenue by 50.3% and 63.5% per annum respectively while EPS is expected to grow by 51.1% per annum.
Key information
50.3%
Earnings growth rate
51.1%
EPS growth rate
Biotechs earnings growth | 34.9% |
Revenue growth rate | 63.5% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 20 Aug 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 16 | -34 | -36 | N/A | 6 |
12/31/2025 | 8 | -26 | -30 | N/A | 7 |
12/31/2024 | 5 | -28 | -23 | 3 | 6 |
6/30/2024 | 6 | -24 | -22 | -22 | N/A |
3/31/2024 | 8 | -24 | -24 | -23 | N/A |
12/31/2023 | 9 | -21 | -29 | -29 | N/A |
9/30/2023 | 9 | -23 | -31 | -31 | N/A |
6/30/2023 | 11 | -22 | -32 | -31 | N/A |
3/31/2023 | 12 | -24 | -33 | -32 | N/A |
12/31/2022 | 15 | -26 | 1 | 1 | N/A |
9/30/2022 | 14 | -49 | 3 | 3 | N/A |
6/30/2022 | 13 | -51 | 4 | 4 | N/A |
3/31/2022 | 9 | -49 | 5 | 6 | N/A |
12/31/2021 | 4 | -43 | -24 | -24 | N/A |
9/30/2021 | 4 | -12 | -24 | -23 | N/A |
6/30/2021 | 2 | -12 | -24 | -23 | N/A |
3/31/2021 | 2 | -14 | -22 | -22 | N/A |
12/31/2020 | 2 | -21 | -20 | -20 | N/A |
9/30/2020 | 3 | -27 | -20 | -20 | N/A |
6/30/2020 | 3 | -36 | -22 | -22 | N/A |
3/31/2020 | 3 | -59 | -28 | -28 | N/A |
12/31/2019 | 4 | -12 | -32 | -32 | N/A |
9/30/2019 | 3 | -52 | -34 | -32 | N/A |
6/30/2019 | 3 | 31 | -35 | -32 | N/A |
3/31/2019 | 5 | 57 | -32 | -30 | N/A |
12/31/2018 | 5 | -46 | -34 | -31 | N/A |
9/30/2018 | 5 | -73 | -33 | -31 | N/A |
6/30/2018 | 6 | -125 | -33 | -31 | N/A |
3/31/2018 | 4 | -133 | N/A | -33 | N/A |
12/31/2017 | 3 | -20 | N/A | -31 | N/A |
9/30/2017 | 4 | 47 | N/A | -34 | N/A |
6/30/2017 | 3 | 64 | N/A | -35 | N/A |
3/31/2017 | 4 | 100 | N/A | -36 | N/A |
12/31/2016 | 6 | 34 | N/A | -42 | N/A |
9/30/2016 | 6 | 25 | N/A | -47 | N/A |
6/30/2016 | 7 | -20 | N/A | -50 | N/A |
3/31/2016 | 8 | -54 | N/A | -50 | N/A |
12/31/2015 | 7 | -47 | N/A | -45 | N/A |
9/30/2015 | 7 | -45 | N/A | -40 | N/A |
6/30/2015 | 6 | -39 | N/A | -37 | N/A |
3/31/2015 | 5 | -39 | N/A | -38 | N/A |
12/31/2014 | 5 | -36 | N/A | -39 | N/A |
9/30/2014 | 5 | -45 | N/A | -38 | N/A |
6/30/2014 | 5 | -46 | N/A | -36 | N/A |
3/31/2014 | 5 | -44 | N/A | -33 | N/A |
12/31/2013 | 4 | -44 | N/A | -30 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BT3 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BT3 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BT3 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BT3's revenue (63.5% per year) is forecast to grow faster than the German market (5.4% per year).
High Growth Revenue: BT3's revenue (63.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BT3's Return on Equity is forecast to be high in 3 years time